Proteomics International (ASX:PIQ)

Executive Summary

Proteomics International Laboratories Ltd (ASX: PIQ) is an Australian med-tech company specializing in protein-based biomarker blood tests for early disease detection. Leveraging large-scale proteomics and mass spectrometry, the company has developed a pipeline of non-invasive diagnostics, including Promarker™D for diabetic kidney disease, Promarker™Eso for esophageal adenocarcinoma, and Promarker™Endo for endometriosis. These products address significant unmet needs in nephrology, oncology, and gynecology. Additionally, the company provides accredited analytical services to pharmaceutical and research partners, generating recurring revenue. With a strong intellectual property portfolio and a commercial-stage focus, Proteomics International is positioned to disrupt traditional diagnostic paradigms through scalable, cost-effective screening tools. In recent quarters, the company has advanced its regulatory and commercial strategy, including expanding Promarker™D's market reach through CE marking and pursuing FDA clearance. Early adoption of Promarker™D in Australia and select international markets has validated its clinical utility. Upcoming milestones include finalizing pivotal trial data for Promarker™Eso and initiating a pivotal study for Promarker™Endo. Collaborations with major diagnostic distributors and pharmaceutical partners are expected to accelerate commercialization. While the company faces competition from other liquid biopsy players, its proprietary technology platform and targeted indications provide a differentiated edge. Management's focus on execution and regulatory timelines will be key to unlocking value.

Upcoming Catalysts (preview)

• Q4 2026FDA or CE Mark approval for Promarker™D70% success
• Q3 2026Pivotal trial data readout for Promarker™Eso60% success
• H1 2027Commercial partnership or licensing deal for Promarker™Endo50% success